Trials / Terminated
TerminatedNCT03514407
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB059872 | Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1. |
Timeline
- Start date
- 2018-06-27
- Primary completion
- 2020-06-25
- Completion
- 2020-06-25
- First posted
- 2018-05-02
- Last updated
- 2025-10-21
Locations
11 sites across 4 countries: United States, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03514407. Inclusion in this directory is not an endorsement.